The quality of prior antithrombotic therapy and the severity of ischemic stroke in atrial fibrillation
https://doi.org/10.14412/2074-2711-2020-5-18-23
Abstract
The severity of neurological disorders in ischemic stroke (IS) in the presence of atrial fibrillation (AF) is known to be higher than that in patients with sinus rhythm. The impact of preventive antithrombotic therapy (ATT) on the clinical manifestations and outcomes of stroke remains a matter of debate.
Objective: to analyze the quality of preventive ATT and to clarify its relationship to the severity of IS in AF.
Patients and methods. The data from the registry of patients (n = 200; 96 (48%) men) (mean age, 71±9 years) with IS and AF were analyzed. Neurological deficit at admission was graded using the National Institutes of Health Stroke Scale (NIHSS). The presence and nature of prestroke antithrombotic therapy were studied.
Results and discussion. Prestroke ATT was performed in 80 (40%) patients, of whom 36 (18%) took antiplatelet agents (APAs). Oral anticoagulants (OACs) were given to 44 patients. The international normalized ratio (INR) in the use of vitamin K antagonists (VKAs) averaged 1.26 [1.11; 1.64]. Neurological deficit was most obvious in the patients who had not previously received ATT (a NIHSS score of 8 [5; 12]). In comparison with them, the regular use of ATT, including APAs and OACs, was associated with the greater likelihood of less severe neurological deficit (a NIHSS of <8): odds ratio (OR), 2.121; 95% confidence interval (CI), 1.178–3.820. The greatest decrease in stroke severity was related to direct (OACs) (DOACs): OR, 2.727 (95% CI, 1.049–7.089), while there was no positive effect of VKAs (OR, 1.534; 95% CI, 0.538–4.377), which was associated with failure to achieve the INR target. Improvement was also related to the prescription of APAs (OR, 2.111; 95% CI, 0.981–4.539).
Conclusion. Preventive ATT for a significant proportion of AF patients does not meet the current recommendations. At the same time, ATT, especially that with DOACs, is associated with the lesser severity of IS.
About the Authors
L. A. Geraskina
Research Center of Neurology
Russian Federation
Russian Federation
Lyudmila A. Geraskina
80, Volokolamskoe Shosse, Moscow 125367
M. M. Alieva
Medical Institute, Peoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery
6, Miklukho-Maklai St., Moscow 117198
A. V. Fonyakin
Research Center of Neurology
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367
M. Yu. Maksimova
Research Center of Neurology
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367
N. I. Garabova
Medical Institute, Peoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery
6, Miklukho-Maklai St., Moscow 117198
M. G. Burzhunova
Medical Institute, Peoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery
6, Miklukho-Maklai St., Moscow 117198
References
1. 2016 ESC Guidelines for the Management of atrial fibrillation developed with EACTS. Rossiyskiy kardiologicheskiy zhurnal = Russ J Cardiol. 2017;7(147):7-86. doi: 10.15829/1560-4071-2017-7-7-86 (In Russ.).
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991 Aug;22(8):983-8. doi: 10.1161/01.str.22.8.983
3. Heemstra HE, Nieuwlaat R, Meijboom M, Crijns HJ. The burden of atrial fibrillation in the Netherlands. Neth Heart J. 2011 Sep;19(9):373-8. doi: 10.1007/s12471-011-0175-4
4. Ceornodolea AD, Bal R, Severens JL. Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat. 2017;2017:8593207. doi: 10.1155/2017/8593207. Epub 2017 May 28.
5. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000 Jan;35(1):183-7. doi: 10.1016/s0735-1097(99)00489-1
6. Perera KS, Vanassche T, Bosch J, et al., on behalf of the ESUS Global Registry Investigators. Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke. Embolic Stroke of Undetermined Source Global Registry. Stroke. 2016;47:2197-202. doi: 10.1161/STROKEAHA.116.013378
7. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.
8. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609- 78. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.
9. Boussier M-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 3:12-9. doi: 10.1159/000209261. Epub 2009 May 14.
10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
11. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke Severity in Atrial Fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760-4. doi: 10.1161/01.str.27.10.1760
12. Shantsila E, Wolff A, Lip GYH, Lane DA. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract. 2015 Jan;65(630):e16-23. doi: 10.3399/bjgp15X683113
13. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006 Aug;92(8):1064-70. doi: 10.1136/hrt.2005.069492. Epub 2005 Dec 30.
14. Hellwig S, Grittner U, Audeberg H, et al. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischemic stroke severity in patients with atrial fibrillation. Europace. 2018 Apr 1;20(4):569-74. doi: 10.1093/europace/eux087
15. Wang C, Yang Z, Wang C, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006
16. Pereverzeva KG, Moseichuk KA, Vorobyev AN, et al. Dynamics of prescribing of oral anticoagulants to outpatients with atrial fibrillation during 2012–2016 according to Registry of cardiovascular diseases (REKVAZA). Kardiologiya: Novosti, Mneniye, Obucheniye. 2017;(1):44-7 (In Russ.).
17. Stepina EV, Loukianov MM, Bichurina MA, et al. Oral anticoagulants in ambulatory and inhospital treatment of patients with atrial fibrillation associated with hypertension, ischemic heart disease and chronic heart failure: Data from Hospital Registry RECVASA-CLINIC. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2017;13(2):146-54. doi: 10.20996/1819-6446-20117-13-2-146-154 (In Russ).
18. Le Heuzey J-Y, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF Registry. Thromb Haemost. 2014;111(5):833- 41. doi: 10.1160/TH13-12-1007
19. Garcia Escriva A, Lopez Hernandez N, Hernandez Lorido R, et al. Modification of clinical profile of stroke in atrial fibrillation patients. Effect of antithrombotic treatment. Rev Neurol. 2004 Mar 1-15;38(5):401-5.
20. Sakamoto Y, Okubo S, Nito C, et al. Insufficient warfarin therapy is associated with higher severity of stroke than no anticoagulation in patients with atrial fibrillation and acute anterior-circulation stroke. Circ J. 2018 Apr 25;82(5):1437-42. doi: 10.1253/circj.CJ-17-1110. Epub 2017 Dec 21.
21. Sakamoto Y, Okubo S, Sekine T, et al. Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation. J Am Heart Assoc. 2018 Sep 4;7(17):e009507. doi: 10.1161/JAHA.118.009507
22. Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010 Feb 1;105(3):411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.
Review
For citations:
Geraskina L.A., Alieva M.M., Fonyakin A.V., Maksimova M.Yu., Garabova N.I., Burzhunova M.G. The quality of prior antithrombotic therapy and the severity of ischemic stroke in atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):18-23. (In Russ.) https://doi.org/10.14412/2074-2711-2020-5-18-23
Views: 350
Email this article 